Journal of Oncology / 2019 / Article / Tab 2

Research Article

Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?

Table 2

Impact of AR/ER, AR/PgR, and ER/PgR ratios on OS in primary tumors of luminal BC patients (no. 89).

Median ratios (range)

AR/ER0.95 (0.06 - 95.00)

AR/PgR1.55 (0.06 - 95.00)

ER/PgR1.60 (0.08 - 90.00)

OS according to best cut-off ratio
Median follow-up: 78 months (range 7 - 155)

no. deaths/no. patientsMedian OS (months)
(95% CI)
HR
(95% CI)
p

Overall55/8963 (46-76)--

AR/ER

<0.9528/4764 (41-82)1.00

≥0.9527/4260 (42-83)1.05 (0.62-1.78)0.861

AR/PgR

<1.5421/3982 (65-89)1.00

≥1.5434/5042 (34-56)2.27 (1.30-3.97)0.004

ER/PgR

<2.0025/4082 (62-88)1.00

≥2.0030/4942 (34-64)1.89 (1.10-3.24)0.021

AR, androgen receptor; ER, estrogen receptor; PgR, progesterone receptor; OS, overall survival; HR, hazard ratio; CI, confidence interval; ND, not determinable; NR, not reached.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.